Loading...
XNASCDXC
Market cap443mUSD
Jan 27, Last price  
5.81USD
1D
-2.35%
1Q
60.50%
Jan 2017
75.53%
IPO
48.97%
Name

Chromadex Corp

Chart & Performance

D1W1MN
No data to show
P/E
P/S
5.31
EPS
Div Yield, %
Shrs. gr., 5y
6.39%
Rev. gr., 5y
21.50%
Revenues
84m
+15.99%
04,506,3015,777,8657,566,3708,112,61011,610,49410,160,96415,313,17922,014,14026,811,08621,201,48231,557,00046,291,00059,257,00067,449,00072,050,00083,570,000
Net income
-5m
L-65.82%
-38,382-2,104,476-907,568-2,051,676-7,894,984-11,662,426-4,419,525-5,388,185-2,771,067-2,928,185-11,377,618-33,316,000-31,471,000-18,483,000-25,557,000-14,449,000-4,938,000
CFO
7m
P
-38,483-1,921,371-396,172-2,661,550-4,098,829-10,119,713-3,906,011-2,580,406-2,111,138-2,936,596-9,804,178-20,908,000-20,439,000-10,600,000-24,163,000-15,098,0007,117,000
Earnings
Mar 04, 2025

Profile

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑00
Income
Revenues
83,570
15.99%
72,050
6.82%
Cost of revenue
89,169
90,678
Unusual Expense (Income)
NOPBT
(5,599)
(18,628)
NOPBT Margin
Operating Taxes
(2,091)
Tax Rate
NOPAT
(5,599)
(16,537)
Net income
(4,938)
-65.82%
(14,449)
-43.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,747
BB yield
-6.61%
Debt
Debt current
1,404
696
Long-term debt
5,852
7,818
Deferred revenue
3,311
3,955
Other long-term liabilities
3,955
Net debt
(20,069)
(11,727)
Cash flow
Cash from operating activities
7,117
(15,098)
CAPEX
(148)
(334)
Cash from investing activities
(143)
(334)
Cash from financing activities
(90)
7,654
FCF
1,446
(20,836)
Balance
Cash
27,325
20,241
Long term investments
Excess cash
23,146
16,638
Stockholders' equity
(190,389)
(185,422)
Invested Capital
226,837
226,261
ROIC
ROCE
EV
Common stock shares outstanding
74,985
69,729
Price
1.43
-14.88%
1.68
-55.08%
Market cap
107,229
-8.46%
117,145
-53.38%
EV
87,160
105,418
EBITDA
(3,894)
(16,744)
EV/EBITDA
Interest
3
Interest/NOPBT